Activities per year
Abstract
Objectives. Analysis of data about newborn’s supraventricular tachycardia (SVT) in Children’s Clinical
University Hospital (CCUH), the type of SVT mechanism, applied treatment, its duration and SVT
complications.
Materials and Methods. This is a retrospective study. Research is comprised of data about newborns
hospitalized to CCUH due to SVT from 2015 to 2020. Data was collected from CCUH patient’s clinical
histories and was analyzed by descriptive statistics methods. Patients were followed-up for 3 to 8 years.
Results. Out of total of 25 patients 21 (84%) were born in time and 4 (16%) were born premature.
SVT mechanism’s types used were: atrioventricular re-entrant tachycardia (AVRT) for 13 (52%) patients,
atrioventricular nodal re-entrant tachycardia (AVNRT) for 4 (16%) patients, ectopic atrial tachycardia (EAT)
for 5 (20%) patients and 3 (12%) patients had not differentiated SVT. Emergency treatment was aplied to 2
(18%) with vagal maneuver, adenosine to 13 (52)% and cardioversion to 3 (12%) of total number of patients.
Preventive therapy was administered to 24 (96%) of patients, out of them 13 (54%) used propranolol. 14
(56%) of patients received therapy until one year of age. On avarage, therapy was received until 11.6 ± 6.7
months of age. 9 (40.9%) of patients followed the same type of therapy from beginning until termination.
SVT complications were observed in 3 (12%) of patients. Anatomical heart defect was diagnosed in 1 (4%)
of newborns with SVT. Other congenital anomalies were in 2 (8%) of patients.
Conclusions. The most common SVT mechanism type is AVRT. The most frequent medical treatment
was propranolol. Mostly, monotherapy for newborns with SVT is effective. Most patient’s heart rhythm
disorders disappeared until one year age. Complications are not common in newborns with SVT. A structural
anatomical heart defect is a rare cause of SVT in newborns. SVT in newborns is not associated with other
congenital anomalies.
University Hospital (CCUH), the type of SVT mechanism, applied treatment, its duration and SVT
complications.
Materials and Methods. This is a retrospective study. Research is comprised of data about newborns
hospitalized to CCUH due to SVT from 2015 to 2020. Data was collected from CCUH patient’s clinical
histories and was analyzed by descriptive statistics methods. Patients were followed-up for 3 to 8 years.
Results. Out of total of 25 patients 21 (84%) were born in time and 4 (16%) were born premature.
SVT mechanism’s types used were: atrioventricular re-entrant tachycardia (AVRT) for 13 (52%) patients,
atrioventricular nodal re-entrant tachycardia (AVNRT) for 4 (16%) patients, ectopic atrial tachycardia (EAT)
for 5 (20%) patients and 3 (12%) patients had not differentiated SVT. Emergency treatment was aplied to 2
(18%) with vagal maneuver, adenosine to 13 (52)% and cardioversion to 3 (12%) of total number of patients.
Preventive therapy was administered to 24 (96%) of patients, out of them 13 (54%) used propranolol. 14
(56%) of patients received therapy until one year of age. On avarage, therapy was received until 11.6 ± 6.7
months of age. 9 (40.9%) of patients followed the same type of therapy from beginning until termination.
SVT complications were observed in 3 (12%) of patients. Anatomical heart defect was diagnosed in 1 (4%)
of newborns with SVT. Other congenital anomalies were in 2 (8%) of patients.
Conclusions. The most common SVT mechanism type is AVRT. The most frequent medical treatment
was propranolol. Mostly, monotherapy for newborns with SVT is effective. Most patient’s heart rhythm
disorders disappeared until one year age. Complications are not common in newborns with SVT. A structural
anatomical heart defect is a rare cause of SVT in newborns. SVT in newborns is not associated with other
congenital anomalies.
| Original language | English |
|---|---|
| Pages (from-to) | 78-78 |
| Number of pages | 1 |
| Journal | Medicina (Kaunas) |
| Volume | 59 |
| Issue number | Suppl.2 |
| Publication status | Published - 2023 |
| Event | RSU Research Week 2023: Research Week 2023 Rīga Stradiņš University - Riga Stradins University, Riga, Latvia Duration: 27 Mar 2023 → 31 Mar 2023 https://rw2023.rsu.lv/general-information https://rw2023.rsu.lv |
Keywords*
- newborn
- supraventricular tachycardia
Field of Science*
- 3.2 Clinical medicine
Publication Type*
- 3.4. Other publications in conference proceedings (including local)
Fingerprint
Dive into the research topics of 'SUPRAVENTRICULAR TACHYCARDIA IN NEWBORNS IN CHILDREN’S CLINICAL UNIVERSITY HOSPITAL (2015–2020)'. Together they form a unique fingerprint.Activities
- 1 Oral presentation
-
Supraventricular Tachycardia in Newborns in Children’s Clinical University Hospital (2015–2020)
Baroņenko, J. (Speaker) & Ligere, E. (Co-author)
29 Mar 2023Activity: Talk or presentation types › Oral presentation